Bristol Myers Squibb’s stock soars

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie shares are down 12.4%. In a statement,
Analysts Predict a $55 Target for Bristol-Myers Squibb Co (BMY) Stock—What Could Drive It There?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and touched a low of $53.
AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie stock.
Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market
Shares of Bristol Myers Squibb Co. BMY inched 0.90% higher to $55.95 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.23% to 5,
Bristol-Myers Hits 14-Month High After AbbVie’s Schizophrenia Drug Fails, Boosting Retail Sentiment
Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after AbbVie's ($ABBV) experimental schizophrenia treatment failed in a pair of mid-stage studies.
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
Buy, Sell, Or Hold BMY Stock?
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Hosted on MSN4h
What's Behind the Insider Buying on This High-Yield Stock?
Bristol-Myers Squibb has demonstrated its commitment to shareholders with ... Overall, the mood on Wall Street is tepid ...
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
What's Next For BMY Stock After An Upbeat Q3?
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
Benzinga.com1d
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
Price Action: AbbVie stock is down 10.6% at $178.32, while Bristol Myers Squibb stock is up 13% at $61.20 during the ...